Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 85Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Leukemia 24Recurrence 16Lymphoma 14Myelodysplastic Syndromes 13Burkitt Lymphoma 13Congenital Abnormalities 12Lymphoma, Non-Hodgkin 10Leukemia, Monocytic, Acute 10Leukemia, Myelomonocytic, Acute 8Leukemia, Erythroblastic, Acute 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Leukemia, Megakaryoblastic, Acute 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Myeloproliferative Disorders 5Lymphoma, Large B-Cell, Diffuse 5Hodgkin Disease 5Multiple Myeloma 4Hematologic Neoplasms 4Blast Crisis 4Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma, B-Cell 3Leukemia, Myelomonocytic, Juvenile 3Leukemia, Biphenotypic, Acute 3Anemia, Refractory, with Excess of Blasts 3Thrombocytopenia 2Primary Myelofibrosis 2Neoplasms, Plasma Cell 2

Interventions

fludarabine 1Everolimus 1Cytarabine 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Leukemia, Prolymphocytic, T-Cell × Cytarabine × Clear all
NCT04526795 2024-12-12

Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia

M.D. Anderson Cancer Center

Phase 1 Terminated
19 enrolled
LymphoidMyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, T-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡